Published in Am J Psychiatry on July 01, 2011
Electronic health records: essential tools in integrating substance abuse treatment with primary care. Subst Abuse Rehabil (2012) 1.55
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat (2014) 0.90
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev (2012) 0.79
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA (2000) 14.17
QTc interval screening in methadone treatment. Ann Intern Med (2009) 5.23
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med (2006) 3.64
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA (2008) 3.64
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther (1994) 2.90
Buprenorphine tapering schedule and illicit opioid use. Addiction (2009) 2.65
Buprenorphine retention in primary care. J Gen Intern Med (2005) 2.57
Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry (2002) 2.56
QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med (2007) 2.07
Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat (1998) 1.98
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend (2005) 1.72
Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend (2006) 1.70
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med (2011) 1.49
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict (2008) 1.45
Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother (2009) 1.45
Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat (2009) 1.44
The "black box" of prescription drug diversion. J Addict Dis (2009) 1.42
Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat (2009) 1.33
Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction (1998) 1.32
Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med (2007) 1.27
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend (2010) 1.27
Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend (2009) 1.25
Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry (2002) 1.23
Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry (2009) 1.18
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend (2009) 1.13
Effects of methadone on QT-interval dispersion. Pharmacotherapy (2005) 1.04
Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int (2001) 1.03
Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction (2010) 1.02
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse (2009) 1.02
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs (2008) 1.01
Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther (2002) 0.96
Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict (2010) 0.92
Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav (2010) 0.89
A new series of 13 buprenorphine-related deaths. Clin Biochem (2002) 0.86
The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother (2009) 0.84
Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend (2005) 4.65
The epidemiology of at-risk and binge drinking among middle-aged and elderly community adults: National Survey on Drug Use and Health. Am J Psychiatry (2009) 4.10
Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol (2007) 2.98
MET meets the real world: design issues and clinical strategies in the Clinical Trials Network. J Subst Abuse Treat (2002) 2.08
Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry (2007) 2.07
The availability of web sites offering to sell opioid medications without prescriptions. Am J Psychiatry (2006) 1.93
Psychiatric symptoms and substance use disorders in a nationally representative sample of American adolescents involved with foster care. J Adolesc Health (2006) 1.91
Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis (2007) 1.82
Racial/ethnic variations in substance-related disorders among adolescents in the United States. Arch Gen Psychiatry (2011) 1.80
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med (2007) 1.70
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat (2006) 1.63
Buprenorphine use: the international experience. Clin Infect Dis (2006) 1.55
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med (2011) 1.49
The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. Subst Abuse Rehabil (2012) 1.44
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat (2004) 1.35
The epidemiology of substance use and disorders among middle aged and elderly community adults: national survey on drug use and health. Am J Geriatr Psychiatry (2009) 1.31
Errors in assessing DSM-IV substance use disorders. Arch Gen Psychiatry (2007) 1.31
Inhalant use among incarcerated adolescents in the United States: prevalence, characteristics, and correlates of use. Drug Alcohol Depend (2007) 1.27
An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study. J Stud Alcohol Drugs (2009) 1.27
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend (2010) 1.27
Screening for alcohol and drug use disorders among adults in primary care: a review. Subst Abuse Rehabil (2012) 1.26
Early data from Project Engage: a program to identify and transition medically hospitalized patients into addictions treatment. Addict Sci Clin Pract (2012) 1.23
Economic costs of nonmedical use of prescription opioids. Clin J Pain (2011) 1.22
Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care (2013) 1.18
Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry (2012) 1.18
Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend (2003) 1.15
Screening instruments for substance use and brief interventions targeting adolescents in primary care: a literature review. Addict Behav (2013) 1.14
The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. Contemp Clin Trials (2008) 1.14
A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage (2006) 1.13
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry (2011) 1.10
Nonprescription use of pain relievers by middle-aged and elderly community-living adults: National Survey on Drug Use and Health. J Am Geriatr Soc (2009) 1.09
Substance abuse, treatment needs and access among female sex workers and non-sex workers in Pretoria, South Africa. Subst Abuse Treat Prev Policy (2009) 1.07
The epidemiology of alcohol use disorders and subthreshold dependence in a middle-aged and elderly community sample. Am J Geriatr Psychiatry (2011) 1.06
Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry (2011) 1.05
Integrating substance abuse care with community diabetes care: implications for research and clinical practice. Subst Abuse Rehabil (2013) 1.04
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res (2011) 1.04
Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction (2010) 1.02
Alcohol limits in older people. Addiction (2012) 1.02
The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis (2006) 1.02
Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf (2005) 1.01
Substance abuse among individuals with intellectual disabilities. Res Dev Disabil (2012) 0.99
Patterns of tobacco use and tobacco-related psychiatric morbidity and substance use among middle-aged and older adults in the United States. Aging Ment Health (2012) 0.99
Treatment use and barriers among adolescents with prescription opioid use disorders. Addict Behav (2011) 0.99
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst Abuse Rehabil (2010) 0.98
Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Subst Abuse Rehabil (2011) 0.98
Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat (2010) 0.97
Conducting research with racial/ethnic minorities: methodological lessons from the NIDA Clinical Trials Network. Am J Drug Alcohol Abuse (2011) 0.97
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol (2008) 0.96
Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res (2011) 0.96
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr (2010) 0.95
Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse (2011) 0.95
Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend (2009) 0.95
Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil (2011) 0.94
Postpartum substance use and depressive symptoms: a review. Women Health (2013) 0.91
A dimensional approach to understanding severity estimates and risk correlates of marijuana abuse and dependence in adults. Int J Methods Psychiatr Res (2012) 0.91
Cocaine use and the occurrence of panic attacks in the community: a case-crossover approach. Subst Use Misuse (2005) 0.91
Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. Drug Alcohol Depend (2011) 0.90
Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil (2011) 0.90
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav (2012) 0.90
Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial. Drug Alcohol Depend (2013) 0.88
Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users. AIDS Behav (2007) 0.87
Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med (2010) 0.87
Substance Use among Adolescent Mothers: A Review. Child Youth Serv Rev (2013) 0.87
Preliminary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil. J Urban Health (2003) 0.87
Compensation effects on clinical trial data collection in opioid-dependent young adults. Am J Drug Alcohol Abuse (2011) 0.86
Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil (2011) 0.83
Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care (2014) 0.83
Injectable extended-release naltrexone for opioid dependence. Lancet (2011) 0.83
Association Between Substance Use and Gun-Related Behaviors. Epidemiol Rev (2016) 0.82
Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse (2011) 0.82
Trends and Correlates of Cannabis-involved Emergency Department Visits: 2004 to 2011. J Addict Med (2016) 0.81
Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug Alcohol Depend (2013) 0.81
Associations between cigarette smoking and pain among veterans. Epidemiol Rev (2015) 0.81
Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict (2009) 0.80
Correlates of handgun carrying among adolescents in the United States. J Interpers Violence (2012) 0.80
Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am (2012) 0.80
Penn/VA center for studies of addiction. Neuropharmacology (2008) 0.79
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Subst Abuse Treat Prev Policy (2012) 0.79
Pharmacologically assisted treatment of opioid-dependent youth. Paediatr Drugs (2013) 0.79
The prevalence and clinical significance of inhalant withdrawal symptoms among a national sample. Subst Abuse Rehabil (2011) 0.79
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev (2012) 0.79
Addiction treatment in Russia. Lancet (2010) 0.79
New horizons: sustained release morphine as agonist treatment. Addiction (2005) 0.79
The science and practice of medication-assisted treatments for opioid dependence. Subst Use Misuse (2012) 0.79
Risk profiles among adolescent nonmedical opioid users in the United States. Addict Behav (2012) 0.79
Trends in nonheroin opioid abuse admissions: 1992-2004. J Opioid Manag (2007) 0.79
Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. J Clin Psychopharmacol (2010) 0.78
Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res (2013) 0.78
NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs. Am J Drug Alcohol Abuse (2011) 0.78
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol (2007) 0.77
Referring heroin users from compulsory detoxification centers to community methadone maintenance treatment: a comparison of three models. BMC Public Health (2013) 0.77
Problem drinking and low-dose naltrexone-assisted opioid detoxification. J Stud Alcohol Drugs (2011) 0.76
Prescribing methadone as an analgesic. Ann Intern Med (2005) 0.76
Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. J Psychiatr Res (2008) 0.76
Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial. J Addict Med (2017) 0.76
Food, class, and health: the role of the perceived body in the social reproduction of health. Health Commun (2012) 0.75
The national drug abuse treatment clinical trials network data share project: website design, usage, challenges, and future directions. Clin Trials (2013) 0.75